MS: a kernel of hope

James McLeod
Med J Aust 2011; 194 (3): . || doi: 10.5694/j.1326-5377.2011.tb04199.x
Published online: 7 January 2011

MULTIPLE SCLEROSIS (MS) is a chronic disabling disease that predominantly affects young women, with onset commonly at the age of 30–35 years. Its prevalence in Australia and elsewhere is steadily increasing. Many treatments have been tried over the years without success but, over the past decade, immunotherapy with beta-interferons and glatiramer has been demonstrated by many clinical trials to reduce the number of relapses and the rate of progression of disability. More recently, natazilumab has proven to be very effective. Unfortunately, all these drugs have side effects and none has yet been able to completely stop, let alone reverse, the progression of the disease.

  • Royal Prince Alfred Hospital, Sydney, NSW



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.